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ABSTRACT 
Despite effective treatment options, more than 40% 
of cancer patients receive inadequate pain manage-
ment. Our previous pilot study resulted in substantial 
adaptations of a cancer pain self-management inter-
vention, the German PRO-Self© Plus Pain Control 
Program originally developed in the United States. 
This program will be implemented into clinical prac-
tice at the Medical Center-University of Freiburg. 
The purpose of this multiple methods pilot study is to 
test the implementation regarding feasibility and ef-
fects in clinical practice. In a randomized, wait-list 
controlled pilot study, adult oncology in-patients of a 
palliative care consultation service with pain >3/10 
will be recruited. The intervention will be performed 
by a specialized advanced practice nurse with an in- 
hospital visit and, after discharge, via phone calls and 
visits. The follow-up will be personalized according to 
a clinical algorithm that factors in pain intensity, sa-
tisfaction with pain management, and patient adhe-
rence. The intervention includes structured and tai-
lored components and is based on three key strategies: 
information, skill building and nurse coaching. The 
specific aims of this study are threefold: 1) to test the 
feasibility of the study and intervention procedures; 2) 
to establish effect sizes of main outcome variables (e.g. 
decrease pain intensity, reduce the number of pa-
tients with pain as main symptom) for subsequent 
power calculation; 3) to explore participants’ expe-
riences with pain self-management support and their 
view of burden and benefit from study participation 
in a qualitative substudy. During the study period, 
which includes three data collection time points (T0 
before, T1 one week and T2 six weeks after dis-
charge), data will be collected via field notes of study 
nurses and questionnaires of patients. The results of 
this pilot study will build the basis for a larger com-
parative effectiveness study in which long term out-
comes of a cancer pain self-management intervention 
in clinical practice will be evaluated. 
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1. INTRODUCTION 
Between 30% and 75% of cancer patients experience 
pain, depending on the type and stage of the illness [1,2]. 
Although effective treatment options exist, more than  
40% of patients with cancer-related pain do not receive 
adequate pain management [3]. Factors that impede pain 
treatment are commonly referred to as barriers to pain 
management [4]. Because oncology treatment takes place 
more and more in the outpatient setting, pain is managed 
mainly at home. As a result, patients’ self-management 
plays a central role in cancer pain treatment and cancer 
pain self-management support interventions are gaining 
increasing attention [5-8]. While statistically significant 
decreases in pain intensity are seen across studies, the 
effects in terms of being clinically meaningful remain in 
the moderate range. Until now, interventions have varied 
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greatly in design, duration, and content, and it remains 
unclear which types of interventions are most effective. 
In addition, clinical feasibility has not yet been the focus 
of research for pain self-management interventions [5-8]. 
1.1. Development of the Self-Management 
Intervention 
Interventions to support cancer pain self-management are 
largely unknown in German-speaking populations. There- 
fore, for a previous pilot study, we translated and adapted 
the PRO-SELF© Plus Pain Control Program (PCP) by 
Miaskowski et al. [9]. This program was found to be 
effective in a large RCT in the United States, and addi-
tional analyses indicated that the revised version, the PRO- 
SELF© Plus PCP, may show even higher effects [10,11]. 
Furthermore, the authors agreed to collaborate closely. 
In a pilot RCT at the Tumorzentrum Ludwig Heil-
meyer – Comprehensive Cancer Center Freiburg (CCCF, 
N = 39), we compared the German PRO-SELF© Plus 
PCP with standard care. The German PRO-SELF© Plus 
PCP was a 10-week program based on three key strate-
gies (information, skill building, and nurse coaching) 
with structured and tailored components. We tested the 
feasibility of instruments and study procedures and cal-
culated effect sizes for pain intensity [12,13]. Effect size 
calculations showed that on the 0 - 10 numeric rating 
scale (NRS) the mean difference of change after 10 
weeks was moderate for average pain (−0.55 [95% CI: 
−2.31/1.20]). For worst pain, the effect size was −0.73 
[95% CI: −2.74/1.28], and the group-by-time effect was 
not statistically significant [12,13]. Using qualitative 
methods, we explored patients’ and family caregivers’ 
experiences with pain management and the intervention 
along with their view of burden and benefit from study 
participation [14,15]. Qualitative findings showed that 
the focus on cancer pain self-management was novel and 
welcomed by participants [14]. However, patients con-
tinued to be ambivalent about their analgesic use, ba-
lancing the need for adequate pain relief with the wish to 
avoid analgesics. Individually tailored counseling helped 
these patients to adapt to the situation [15]. 
1.2. Implications of the First Pilot Study for the 
Proposed Project 
The pilot study provided us with the opportunity to learn 
from methodological difficulties [13]. Although the 
transfer and pilot testing of the German PRO-Self© Plus 
PCP was quite successful and the feasibility of research 
and intervention procedures was established, a number of 
aspects warrant critical consideration. A low response 
rate indicates that the invitation to participate needs to be 
more closely linked to clinical practice. A high attrition 
rate (18% in six weeks; 35% in 22 weeks) may be in-
evitable and should be considered for sample size calcu-
lations. 
Furthermore, it appears that the dynamic nature of 
cancer pain was not completely accounted for within the 
fixed structure of the intervention. We thus decided to 
break up the structure of the PRO-SELF© Plus PCP and 
tailor it more closely to patients’ individual pain situa-
tions by developing a precise clinical algorithm for fol-
low-up. In addition, this new structure facilitated the 
clinical feasibility of the intervention. 
Some side effects of cancer treatment (e.g., nausea) 
will be addressed because they severely impacted pain 
self-management. Most patients in the pilot study took 
rather low doses of opioid analgesics for their cancer pain, 
and daily opioid intake did not increase over time. The 
intervention will therefore be combined with a palliative 
care consultation in which state-of-the-art medical treat- 
ment will be prescribed. Furthermore, patients’ adherence 
to prescriptions and the intervention should be evaluated 
more regularly in the nurse coaching component. 
Regarding outcome assessments, results showed that 
reduction of pain intensity as a primary outcome may not 
have comprehensively reflected the effect of the pain 
self-management intervention [13]. Patients experienced 
more than one symptom in our previous study. Subse-
quently, health-related quality of life was not affected by 
the intervention [12]. Likewise, it was difficult to assess 
the influence of pain on patients’ functioning. In addition 
to pain, several other symptoms (e.g. fatigue) often in-
terfered with functioning, and patients had difficulties 
distinguishing between the symptoms’ effects on func-
tioning [13]. In contrast, the self-developed item “The 
pain hindered me to do the things that I wanted to do 
today” showed a significant group-by-time interaction 
effect between the intervention and the control group at 
week 10 (p = 0.02; Cohen’s d = −0.54) [12]. The pro-
posed study may be used to evaluate suitable primary 
and secondary outcomes. However, patient burden was 
an issue mentioned by patients in our last study. There-
fore, patients should be provided a comprehensive choice 
of influencing secondary outcomes without having to 
complete additional questionnaires. 
A first version of the advanced pain self-management 
intervention is now in the process of implementation in 
clinical practice (timetable, see Table 1). However, fur-
ther pilot testing is needed to tailor the program optimal-
ly to the health care needs of the German context, not 
only because significant adjustments were made to the 
program but also because the clinical context may de-
mand further refinement. 
1.3. Aims of the Study 
The purpose of this multiple methods pilot study is to  
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Table 1. Timetable. 
Time Activity or Milestone 
April 2013-Nov 2013 
Pre-test of intervention and recruitment  
procedures, implementation of intervention  
(not included in project time) 
Project activities will start December 2013 
Dec 2013-Nov 2014 
Study coordination recruitment, data entry  
and quality assurance, preparation of data  
analysis (study coordinator) 
Data collection, qualitative interviews, 
data entry (1st [blinded] study nurse) 
Intervention nurse for recruitment and 
intervention, quality assurance of protocol 
fidelity (2nd study nurse) 
Jan 2014-Mar 2015 
Data entry, data quality assurance, and 
qualitative interviews (study nurse) 
Data analysis, preparation of publications 
(AK) 
Apr 2015-May 2015 Publications (AK) 
 
test the implementation of an advanced cancer pain 
self-management support intervention in light of its fea-
sibility and effects within the clinical context. 
The primary aim is to establish key features for a ran-
domized clinical trial of the advanced pain self-mana- 
gement support intervention in a clinical context. The 
specific aims are threefold: 1) to test the feasibility of the 
study and intervention procedures; 2) to establish effect 
sizes of main outcome variables (e.g. reduce pain inten-
sity, reduce the number of patients with pain as the main 
symptom, increase patient satisfaction with pain man-
agement) for subsequent power calculation; 3) to explore 
participants’ experiences with pain self-management 
support and their view of burden and benefit from study 
participation in a qualitative substudy. 
2. METHODS 
2.1. Design 
The advanced pain self-management support intervention 
will be compared with standard care. A randomized, 
wait-list controlled pilot study will be performed with 
patients of the palliative care consultation service at the 
Medical Center-University of Freiburg (timetable see 
Table 1). The palliative care consultation service has 
been implemented to improve care for hospitalized, in-
curably ill patients with increased supportive care needs. 
This service is used by clinicians in all departments of 
the Medical Center. Patients will be randomized in an 
intervention and a wait-list control group. A qualitative 
sub-study will be performed with patients of both groups 
to compare their experiences. 
2.2. Effects and Risks 
Benefit of study participation: Patients in both groups 
will learn how to measure and document their pain and 
associated symptoms. Patients in the intervention group 
will obtain new knowledge about their pain and will re-
ceive self-management support. As soon as the six-week 
study period following discharge is over and the qualita-
tive interviews have been completed, patients in the con-
trol group will also be offered the intervention. 
Potential risks of study participation: During the qua-
litative interviews, patients may experience strong emo-
tions that are related to their pain and disease. In this 
case, they will be offered to interrupt or stop the inter-
view. Patients in the intervention group may take more 
analgesics and experience more side effects. However, 
pain treatment will be prescribed according to state-of- 
the-art guidelines [16] and patients will be supported in 
monitoring and managing their side effects. 
2.3. Sample Size Calculation 
Assuming the previous study’s attrition rate of 18% at 
six weeks, 48 adult oncology in-patients will be recruited 
to achieve a sample of N = 40 patients with full data sets 
at the end of the study. Over the last 6 months, the pallia-
tive care consultation service consulted approximately 35 
patients with cancer-related pain. Assuming a response 
rate of 70%, a recruitment period of 12 months seems 
reasonable. 
2.4. Methods of Randomization 
After informed consent and baseline data collection, pa-
tients will be randomized 1:1 into the intervention and 
the control group. Group allocation will be concealed 
from study personnel by using a computer generated list 
with randomly permuting block lengths. A study nurse 
will prepare opaque envelops, which will be ordered and 
kept in a box accessible to recruiting personnel. 
2.5. Inclusion Criteria 
Patients will be included if they:  
• have cancer-related pain >3 (NRS 0 = no pain to 10 = 
worst pain imaginable), 
• will be discharged from hospital and will self-manage 
their pain after discharge, 
• have an expected life expectancy of ≥ 3 months, 
• understand, read and write German, 
• and have access to a telephone. 
2.6. Exclusion Criteria 
Patients will be excluded if their treating physicians 
perceive that they have severe cognitive deficits. Attri-
tion is expected to occur mostly because of deterioration 
of the patients’ health status. Therefore, data that were 
collected before hospitalization will be included in the 
analysis unless patients explicitly withdraw their consent. 
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Patients who are hospitalized for less than two weeks 
will resume the study after discharge. 
2.7. Study Procedures 
Recruitment: Patients will be screened for potential eli-
gibility by the palliative care consultation service. For all 
patients, the palliative care consultation service will 
recommend state-of-the-art pain treatment [16] and con-
tact an intervention nurse. Intervention nurses will be 
specifically trained Bachelor prepared nurses with pro-
found experience in oncology nursing. The recommen-
dation for pain treatment will be carried out by health 
care professionals on the wards. The intervention nurse 
will verify in- and exclusion criteria, inform patients 
about the project and invite them to participate. 
Data collection: After written informed consent and 
before randomization, baseline data will be collected by 
the intervention nurse. At one and six weeks after dis-
charge, data collection will be performed by a blinded 
study nurse via mail and telephone. If patients are hospi-
talized for more than two weeks during the six-week 
study period following discharge, they will be excluded 
from further study participation. 
Interventions: Patients in the control group will not 
receive additional pain self-management support during 
the study. After the six-week study period of following 
discharge and the qualitative interview, patients in the 
control group will be offered pain self-management 
support by an intervention nurse. 
Patients in the intervention group will be offered pain 
self-management support by the intervention nurse who 
will be required to follow a detailed intervention protocol. 
For patients in the intervention group, the intervention 
nurse will carry out the first session of the cancer pain 
self-management support intervention in the hospital. If a 
family caregiver is involved in the patient’s pain self- 
management, they will be invited to participate in the 
intervention. The intervention will consist of a face-to- 
face session during the inpatient stay, follow-up phone 
calls, and face-to-face contacts according to the patient’s 
further treatment schedule. Provision of information and 
skill building will be provided mainly during the first 
session, whereas the nurse coaching component will be 
provided mainly after discharge. Patient follow-up will 
continue until the pain situation has been stabilized ac-
cording to a clinical algorithm based on pain intensity, 
satisfaction with pain management and adherence to 
analgesic medication and recommendations. 
The intervention will be designed to provide structured 
and tailored components. Structured intervention com-
ponents include an initial assessment of the patient’s pain, 
side effects and experiences with pain management. 
Furthermore, all participants will be trained to monitor 
their pain, other symptoms and analgesic intake. Based 
on the patient’s answers on a questionnaire, the interven-
tion nurse will guide a discussion about the patient’s at-
titudes and knowledge regarding pain management (aca-
demic detailing teaching approach [17]) and hand out a 
corresponding booklet. Tailored intervention components 
include information and practical advice about each pa-
tient’s analgesic prescription and corresponding side 
effects, information about how to communicate with 
clinicians if pain control is inadequate and changes are 
needed in the analgesic prescription, as well as the use of 
a weekly pillbox. 
At the end of each visit, the patient will have detailed, 
written pain and side-effect management plans that pro-
vide a list of the discussed strategies. In addition, a time 
for the next contact will be scheduled according to the 
criteria provided in the algorithm. At each follow-up 
contact, adherence to analgesic medication and the rec-
ommendations of the last contact will be assessed and 
discussed with the patient. In addition, the patient will be 
screened for side-effects and other relevant symptoms. 
Quality control: All intervention nurses will follow a 
detailed intervention protocol. To ensure protocol fidelity, 
adherence of each intervention nurse will be monitored 
with audio tapes of the first visits. A second intervention 
nurse will listen to the tapes and give feedback to the 
intervention nurse in order to reach approximately 90% 
adherence to the intervention protocol. After adherence 
has been achieved, a random sample of ~10% of the 
contacts will be audiotaped and controlled. These meas-
ures have been used successfully in the previous study. 
2.8. Statistical Design 
Variables and measurement: To address the first spe-
cific aim, the semi-structured field notes and qualitative 
interviews will be analyzed. The field notes will be taken 
at each contact, including time and content of the inter-
vention as well as information about any experiences 
with the intervention procedures and content. The field 
notes and qualitative interviews will be analyzed based 
on the following feasibility criteria: acceptability, de-
mand, implementation, practicality, adaptation, integra-
tion, expansion, and limited efficacy (see Table 2) [18]. 
For the second aim, the primary outcome will be pain 
intensity. We will also assess the following secondary 
outcomes: The number of patients with pain as chief 
symptom, side-effects, patient satisfaction with pain 
management and information about pain management, 
pain interference with function, adherence to analgesic 
medication and the intervention nurse’s recommenda-
tions, quality of life, knowledge and attitudes towards 
pain management, as well as pain-related self-efficacy. 
Outcomes will be assessed in light of effect sizes and        
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Table 2. Key areas of focus for feasibility studies and possible outcomes [18]. 
Area of focus The feasibility study asks… Selected outcomes 
Acceptability 
To what extent is a new idea, program, process or  
measure judged as suitable, satisfying, or attractive 
to program deliverers? To program recipients? 
• Satisfaction with pain management 
• Intent to continue use 
• Perceived appropriateness 
• Recruitment rate and response rate 
• Expressed interest or intention to use Demand 
To what extent is a new idea, program, process, or 
measure likely to be used (i.e., how much demand 
is likely to exist?) 
Implementation 
To what extent can a new idea, program, process, or measure 
be successfully delivered to intended participants in some 
defined but not fully controlled context? 
• Degree of execution 
• Success or failure of execution 
• Amount, type of resources needed to implement 
• Factors affecting implementation ease or difficulty 
• Positive/negative effects on target participants 
• Ability of participants to carry out intervention activities 
Practicality 
To what extent can an idea, program, process, or 
measure be carried out with intended participants 
using existing means, resources, and circumstances 
and without outside intervention? 
Adaptation 
To what extent does an existing idea, program, process, 
or measure function when changes are made for a new 
format or with a different population? 
• Comparison between intervention group and standard care group 
Integration To what extent can a new idea, program, process, or measure be integrated into an existing system? 
• Not within the scope of this study 
Expansion 
To what extent can a previously tested program, 
process, approach, or system be expanded to provide 
a new program or service? 
Limited efficacy 
Does the a new idea, program, process, or measure  
show promise of being successful with the intended 
population, even in a highly controlled setting? 
• Effect-size estimation 
• Perceived effect of patients in both groups 
 
fit with the study aim. Demographic and clinical data, 
functional status, the patient’s initial preference of study 
arm, as well as the dose of and adherence to the interven-
tion will be measured as covariates. 
Table 3 provides a listing of variables and instruments 
and times of measurement. Data for each patient will be 
collected at baseline (T0), and one (T1) and six weeks 
(T2) after discharge. 
Demographic data will include age, gender, years of 
formal education (school and vocational training, univer-
sity, etc.), profession, living condition (i.e., alone or not), 
and information about family support. Clinical data will 
include type of tumor, comorbidities, time since tumor 
diagnosis, and time since pain onset. Most information 
will be obtained from medical records. Additional data 
(e.g. educational status) will be obtained from the pa-
tients via questionnaire. 
Eastern Cooperative Oncology Group Performance 
Status (ECOG-PS): Functional status will be measured 
with the ECOG, referring to the patient’s capacity to 
perform a variety of activities that are normal for most 
people [19]. The German version will be used [20]. 
Depression will be measured with the PHQ-2, a 2-item 
screening tool [21]. Decrease of interest and dejectedness 
are measured each on 0 (never) to 3 (almost every day). 
Sensitivity and specificity to detect depressive disorders 
were 79% and 56% with a cutoff of ≥3 and Crohnbach’s 
α was 0.83 [21]. 
Brief Pain Inventory (BPI): The BPI is a comprehen-
sive self-report questionnaire to assess pain management 
in 5 dimensions: pain intensity, analgesic intake, pain 
alleviation, pain location and pain interference with 
functioning [22]. Pain intensity, i.e. average, least and 
worst pain, and pain right now, are each measured on a 0 
(none) to 10 (worst imaginable pain) NRS. Around-the- 
clock and as-needed medication taken in the last 48 
hours will be listed by the patient. Patients will rate the 
alleviation that they obtained from this medication on a 0 
(no alleviation) to 100 (complete alleviation) scale. Pa-
tients will be asked to draw the location of their pain by 
shading the affected areas of their body on a body map. 
In addition, they will be asked to make a cross on the 
most affected body part. Pain interference with function-
ing is a 7-item scale in which patients are asked to eva-
luate how pain has interfered with a variety of activities 
during the past week using a scale from 0 (does not in-
terfere) to 10 (completely interferes). Scores on the indi-
vidual items will be summed and divided by 7 to obtain a 
total interference score that ranges from 0 to 10. The BPI 
has established validity and reliability [23]. The α relia-
bility for the scale ranges from 0.91 to 0.95 [22]. 
Main symptom and side-effects of pain and cancer 
treatment: In the Memorial Symptom Assessment Scale 
(MSAS), patients report the presence of 32 symptoms. 
The checklist has been developed for cancer patients by 
Portenoy et al. [24] Symptom occurrence (i.e. frequency     
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Table 3. Listing of study variables and instruments. 
Variables Measurement Number of items filled out by patients 
Demographic dataT0 Patient information questionnaire 10 items 
Clinical dataT0 Medical record review form  
Functional statusT0, T1, T2 Eastern Cooperative Oncology Group Performance Status 1 item 
Depression T0, T1, T2 PHQ-2 2 items 
Average and worst pain intensity T0, T1, T2 
Around-the-clock and “as-needed” analgesic medication 
Pain alleviation from pain medication 
Pain location  
Pain interference with functioning 
Brief Pain Inventory 12 items 
Side-effects of pain and cancer treatment T0, T1, T2 Memorial Symptom Assessment Scale (MSAS) 35 items 
Main symptoms T0, T1, T2 Rank order question of 3 main symptoms of the MSAS 3 items 
Patient satisfaction with pain management T0, T1, T2 0 - 10 numeric rating scale; self-developed 1 item 
Patient satisfaction with information about pain treatment T1 0 - 10 numeric rating scale; self-developed 1 item 
Adherence to analgesic therapy T1, T2 0 - 100 numeric rating scale 1 item 
Adherence to recommendations of intervention nurse T1, T2 0 - 100 numeric rating scale 1 item 
Quality of life T0, T1, T2 Medical Outcomes Study-Short Form (SF-12) 12 items 
Knowledge of cancer pain T0, T1, T2 Barriers Questionnaire (BQ II) 27 items 
Importance of analgesic intake T0, T1, T2 0 - 10 numeric rating scale; self-developed* 1 item 
Pain-related self-efficacy 0 - 6 numeric rating scale (FESS) 10 items 
The pain hindered me to do things that I wanted to do today T1, T2 0 to 10 numeric rating scale; self-developed 1 item 
Patient preference for study arm T0 10 cm visual analogue scale; self-developed 1 item 
Variables derived from analgesic intake  
Adequacy of analgesic prescription T0, T1, T2 Pain Management Index (PMI) 
Opioid intake T0, T1, T2 Morphine equivalent 
Complexity of analgesic regimen 
Number of different analgesics  
Number of time-points of analgesic intake 
Number of other medications 
Additional variables for intervention and post intervention data collection I 
Time spent with intervention nurse In minutes 
Dose of intervention: topics covered Checklist of topics covered during intervention 
Dose of intervention: duration Time spent 
Adherence to the intervention Checklist of pain management strategies; yes, no 
T0collected at baseline; T1collected at T1, one week after discharge; T2collected at T3, six weeks after discharge; Icollected at interventions; *rated independently 
by the patient and the study nurse 
 
and severity) and symptom distress are rated for present 
symptoms. Eight symptoms are evaluated only in terms 
of severity and distress since using a frequency scale is 
not meaningful (e.g. weight loss). Three additional lines 
allow for patients to list symptoms that are not included. 
Symptoms are scored on a four-point Likert scale (1 - 4) 
for frequency and severity, and on a five-point Likert 
scale (0 - 4) for distress. In this study, the German ver-
sion of Spichiger et al. [20] will be used. Patients will be 
asked if they have one, two, three or no main symptoms. 
They will then be asked to rank these by putting the 
numbers 1 (main symptom) to 3 (third main symptom) 
next to the symptoms. 
Patient satisfaction with pain management will be as-
sessed with an 11-point NRS (0 = not satisfied at all to 
10 = completely satisfied) at T1. Patient satisfaction with 
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information about pain treatment will be assessed with 
an 11-point NRS (0 = not satisfied at all to 10 = com-
pletely satisfied) at T2 and T3. 
Adherence to prescribed analgesics and the interven-
tion: Patient self-report is a useful method to assess ad-
herence to self-management support interventions [25]. 
Patients will rate their adherence to the medical prescrip-
tion and adherence to the noted recommendations for 
pain self-management from the previous visit with a 
NRS respectively (0 = no adherence at all; 100 = com-
plete adherence). 
Medical Outcomes Study-Short Form (SF-12): This 
12-item instrument is designed to measure quality of life 
by assessing health concepts that are relevant to a per-
son’s functional status and well-being. The SF-12, in-
cluding the German version, has been demonstrated to be 
reliable and valid in clinical and population-based appli-
cations in the U.S. and other countries [26-29].  
Knowledge of and attitudes towards cancer pain: 
These variables will be evaluated with the Barriers Ques-
tionnaire-II (BQ-II), which is a self-report instrument 
originally developed in 1993[30]. After its revision [31], 
the BQ-II, consisted of 27 items addressing eight com-
mon barriers (i.e., concerns about addiction, tolerance, 
side effects, about distracting the physician from treating 
the cancer, that pain medications may impair the immune 
system, and analgesics may mask pain as sign of warning; 
fatalism; and the belief that “good” patients do not com-
plain about pain). Items are scored on 6-point Likert 
scales anchored with 0 (do not agree at all), and 5 (agree 
very much). The BQ-II showed a high level of internal 
consistency (α = 0.9) [31]. In addition, the importance of 
taking their analgesic medication will be assessed in pa-
tients with acute or imminent pain by asking, “How im-
portant do you think is it for you at the moment to take 
your analgesic medication?” on a scale of 0 (not at all) to 
10 (extremely important). Based on the patients’ pain 
levels and the potential reasons for having pain, the study 
nurse will independently rate her view of the importance 
of that patient taking their analgesic medication on a 
scale of 0 (not important) to 10 (extremely important) . 
The nurse will also write down a short clinical reasoning 
for her judgment. 
Self-efficacy will be measured with the German adap-
tation of the Pain Self-efficacy Questionnaire (FESS) 
[32]. The FESS is a 10-item scale. Patients rate each of 
the items regarding their perceived ability to manage 
various aspects of their pain on scales of 0 (very uncer-
tain) to 6 (very certain). Crohnbach’s alpha for the Ger-
man version was 0.93 [32]. In addition, we use the 
self-developed item from our previous study [12], by 
asking the patients to rate “The pain hindered me to do 
things that I wanted to do today.” on a 0 (not at all) to 10 
(completely) scale. 
Preference for study arm: To assess whether patient 
preference for the intervention has an influence on out-
comes, the patients’ degree of preference for the inter-
vention or the wait-list control study arm will be assessed 
using a 10 cm long visual analogue scale (left end: “I 
would absolutely prefer to be in the intervention group”, 
right end “I would absolutely prefer to be in the wait-list 
control group” and an indication at 5 cm marked as “I do 
not have a preference for either of the two groups”). Be-
fore answering the question, patients will be informed 
that their preference will not have an effect on their ran-
domization in this pilot study but that the results of this 
item will be used to plan the design of a larger study 
[33]. 
Variables derived from analgesic intake: The Pain 
Management Index (PMI) is a composite measure to 
assess the adequacy of analgesic prescription. It is com-
puted by subtracting a patient’s worst pain intensity from 
the rating of the most potent analgesic prescribed [34]. 
Scores can range from −3 to 3, with negative scores in-
dicating low adequacy. The PMI is one of the most used 
outcome measures for quality of pain treatment [35-37]. 
Opioid intake per day: All doses of opioids will be 
converted to morphine equivalents per 24 hours. Total 
and ATC doses of the opioid analgesics taken by patients 
will be calculated. 
Complexity of analgesic regimen: The number of dif-
ferent analgesics, number of points in time as well as the 
number of other medications will be calculated for each 
patient. 
Data analysis: Data files will be analyzed using IBM 
SPSS Statistics 19.0. Data will be systematically ex-
amined for out of range values and data inconsistencies. 
Appropriate descriptive statistics will be calculated for 
all study variables. The analysis will follow an in-
tent-to-treat strategy with a level of significance at 0.05. 
Although withdrawal is expected to be a random process, 
participants who completed the study and those who did 
not will be compared based on demographics, treatment 
group and other salient variables. Change scores for each 
patient as well as Cohen’s d will be calculated for each 
variable of interest. To determine differences between 
the change scores of the pre- and the post-assessments 
regarding average and worst pain intensity between the 
two groups, regression analysis will be applied. 
2.9. Qualitative Substudy 
Recruitment: A sample of 10 - 12 patients seems rea-
sonable to reach sufficient redundancy in the data. In the 
beginning, consecutive patients will be invited to partic-
ipate. Later, purposive sampling will be used to ensure 
variation (e.g., regarding age, gender, education, occupa-
tion, living situation, tumor entity and disease status).     
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Table 4. Main questions for semi-structured interview guide (Patients of both groups will be asked the same questions). 
Opening generic question 
Follow-up questions 
Maybe we could start with how you experienced your pain management during the study?* 
How was the pain management shortly before discharge? How was it after you were discharged? 
In your opinion, has the study influenced the way you dealt with your pain at home? If it did, in which way? 
Intervention procedures 
Follow-up questions 
When you think of your first visit with Mrs. XX before you were discharged, what was your experience then? 
After you were discharged, how did the study go on for you? 
Study procedures 
Follow-up questions 
Were there any organizational issues while taking part in the study? 
What did you think of the burden and benefit of study participation?  
For the study, you filled out several questionnaires, what did you think of that? 
Were there any questions difficult to answer in the questionnaires? 
There is one question in particular. What are your thoughts when answering the question: 
“The pain hindered me to do the things that I wanted to do today” 
Closing remarks Do you have anything else that you would like to tell the study leader? If you had a close friend with cancer-related pain, would you recommend taking part in the study? 
*The leading question is printed bold; follow-up questions will only be asked if these topics have not been covered spontaneously by the participants. The 
general interview technique will include questions like “Can you think of anything else?” or “Could you tell me some more details about this?” to maintain the 
participants’ flow of speech. Each leading question will be printed on a card together with the follow-up questions to guide the interview nurse during the inter-
view. 
 
Data collection: Patients of both groups will be inter-
viewed according to a semi-structured interview guide by 
a study nurse who has not been involved in the interven-
tion. The interview will start with a generic question 
about the participants’ experience with their pain man-
agement during the study period (see Table 4). More 
focused questions will be asked about their experiences 
with the feasibility of the intervention and their view of 
the data collection procedures. Interview nurses will be 
trained on how to interview patients according to the 
interview guide and how to maintain a flow of speech. 
Data analysis: The interviews will be audio recorded, 
transcribed verbatim and analyzed using qualitative con-
tent analysis as described by Mayring [38]. This will 
include a stepwise and systematic processing and reduc-
tion of data leading to a meaningful synopsis. After the 
first interview, the project leader will listen to the tapes 
and give feedback to the interview nurse. Ongoing tran-
scription and analysis during the recruitment period will 
allow adaptation of the interview guide during the study 
if necessary. 
2.10. Ethical and Legal Aspects 
• The study will be performed according to the Decla-
ration of Helsinki. 
• Ethical approval has been obtained from the local 
ethical board. 
• Participation of patients is entirely voluntary. Patients 
are free to withdraw their consent at any time without 
any disadvantages for their medical treatment or 
nursing care. Patients will give written, informed 
consent after comprehensive oral and written infor-
mation. Furthermore, patients will be informed that 
already collected data will be used in pseudomized 
form if they do not explicitly state otherwise. 
• Data will be pseudomized by using a numerical ID. 
The master file with patient names and ID number 
will be kept on local servers of the clinic and will be 
locked via a password that will only be known by the 
project leader and her substitutes. 
3. CONCLUSION 
The results of this pilot study will build the basis for a 
larger comparative effectiveness study in which long 
term outcomes of a cancer pain self-management inter- 
vention will be evaluated with a strong focus on feasibil- 
ity in clinical practice. 
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LIST OF ABBREVIATIONS 
ATC: around the clock 
BPI: Brief Pain Inventory 
BQ-II: Barriers Questionnaire-II 
CCCF: Tumorzentrum Ludwig Heilmeyer – Compre-
hensive Cancer Center Freiburg 
ECOG-PS: Eastern Cooperative Oncology Group Per-
formance Status 
FC: family caregiver 
FESS: Pain Self-efficacy Questionnaire 
MSAS: Memorial Symptom Assessment Scale 
NRS: numeric rating scale 
PHQ 2: Patient Health Questionnaire Depression short 
form 
PI: Pain Management Index 
PRO-Self© Plus PCP: PRO-Self© Plus Pain Control 
Program 
RCT: randomized controlled trial 
SF-12: Medical Outcomes Study-Short Form 
T0: baseline 
T1: one week after discharge 
T2: six weeks after discharge 
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